share_log

港股异动 | 艾迪康控股(09860)逆市涨超5% 23年股东应占溢利同比减少65.5% 特检业务增长显著

Changes in Hong Kong stocks | Addicon Holdings (09860) reversed the market and rose more than 5%. Profit attributable to shareholders in '23 decreased 65.5% year-on-year, and the special inspection business grew significantly

Zhitong Finance ·  Apr 15 23:53

Adicom Holdings (09860) reversed the market and rose by more than 5%. As of press time, it rose 5.59% to HK$12.46, with a turnover of HK$9.45 million.

The Zhitong Finance App learned that Adicon Holdings (09860) reversed the market and rose by more than 5% and rose 5.59% at press time to HK$12.46, with a turnover of HK$9.45 million.

In terms of performance, the company's results for the year ended December 31, 2023. The group achieved revenue of 3.298 billion yuan (RMB, same below) during the period, a year-on-year decrease of 32.15%; profit attributable to owners of the parent company was 235 million yuan, a year-on-year decrease of 65.5%; and a basic profit of 0.34 yuan per share. According to the announcement, the decline in revenue was mainly due to a sharp drop in demand for the Group's COVID-19-related services. However, as COVID-19 restrictions were lifted, demand for the Group's non-COVID-19 testing services picked up.

According to Sullivan's data analysis, the growth rate of the special testing business is expected to be faster than general testing, and it will occupy a larger and larger share of the overall clinical laboratory market. In 2023, the company's special testing business grew significantly, with a year-on-year increase of 43%. At the same time, the special inspection business also promoted a 7% year-on-year increase in the company's ASP; all disease lines achieved considerable year-on-year growth. Among them, infection programs increased 66% year over year, oncology programs increased 35% year over year, maternal and child programs increased 32% year over year, and blood programs increased 33% year over year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment